11 Best NASDAQ Penny Stocks To Buy Right Now

4. Geron Corporation (NASDAQ:GERN) 

Number of Hedge Fund Holders: 29

Stock Price as of December 4: $3.95

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company that has made a strong start to its commercial journey with its flagship product, imetelstat, a disease-modifying treatment for lower-risk myelodysplastic syndromes (LR-MDS), an abnormal blood cell production disorder in the bone marrow. Geron Corporation’s (NASDAQ:GERN) primary revenue stream comes from the sales of imetelstat, which affects approximately 25,000 patients in the United States. The company’s clients are primarily hematologists and oncologists who treat patients with LR-MDS, a market that is expected to grow significantly as the product gains traction.

Geron Corporation (NASDAQ:GERN) is focused on expanding its commercial reach, both in the United States and internationally. The company has secured favorable funding deals with Royalty Pharma and Pharmakon Advisors, which provided $375 million in non-dilutive financing to support commercialization efforts. The company plans to use these funds to invest in sales and marketing initiatives, expand its commercial team, and build out its distribution network. Geron Corporation (NASDAQ:GERN) is also pursuing additional indications for imetelstat, including a marketing authorization application (MAA) review in the European Union for lower-risk MDS, which could lead to approval in early 2025.

In addition to its commercial efforts, Geron Corporation (NASDAQ:GERN) is advancing its pipeline with several ongoing clinical trials, including a Phase 3 study in relapsed/refractory myelofibrosis (MF) patients, a condition with no curative treatments. The company expects interim data from this study in early 2026, with topline results anticipated in early 2027.